These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

660 related items for PubMed ID: 24410571

  • 1. Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapy.
    Zhao Y, Morgan MA, Sun Y.
    Antioxid Redox Signal; 2014 Dec 10; 21(17):2383-400. PubMed ID: 24410571
    [Abstract] [Full Text] [Related]

  • 2. Inactivation of the Cullin (CUL)-RING E3 ligase by the NEDD8-activating enzyme inhibitor MLN4924 triggers protective autophagy in cancer cells.
    Luo Z, Pan Y, Jeong LS, Liu J, Jia L.
    Autophagy; 2012 Nov 10; 8(11):1677-9. PubMed ID: 22874562
    [Abstract] [Full Text] [Related]

  • 3. Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells.
    Lan H, Tang Z, Jin H, Sun Y.
    Sci Rep; 2016 Apr 11; 6():24218. PubMed ID: 27063292
    [Abstract] [Full Text] [Related]

  • 4. Suppression of glioblastoma by targeting the overactivated protein neddylation pathway.
    Hua W, Li C, Yang Z, Li L, Jiang Y, Yu G, Zhu W, Liu Z, Duan S, Chu Y, Yang M, Zhang Y, Mao Y, Jia L.
    Neuro Oncol; 2015 Oct 11; 17(10):1333-43. PubMed ID: 25904638
    [Abstract] [Full Text] [Related]

  • 5. Targeting protein neddylation with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis or senescence in human lymphoma cells.
    Wang Y, Luo Z, Pan Y, Wang W, Zhou X, Jeong LS, Chu Y, Liu J, Jia L.
    Cancer Biol Ther; 2015 Oct 11; 16(3):420-9. PubMed ID: 25782162
    [Abstract] [Full Text] [Related]

  • 6. Suppression of tumor angiogenesis by targeting the protein neddylation pathway.
    Yao WT, Wu JF, Yu GY, Wang R, Wang K, Li LH, Chen P, Jiang YN, Cheng H, Lee HW, Yu J, Qi H, Yu XJ, Wang P, Chu YW, Yang M, Hua ZC, Ying HQ, Hoffman RM, Jeong LS, Jia LJ.
    Cell Death Dis; 2014 Feb 13; 5(2):e1059. PubMed ID: 24525735
    [Abstract] [Full Text] [Related]

  • 7. Targeting DCN1-UBC12 Protein-Protein Interaction for Regulation of Neddylation Pathway.
    Zhou H, Lu J, Yang CY, Sun Y, Wang S.
    Adv Exp Med Biol; 2020 Feb 13; 1217():349-362. PubMed ID: 31898237
    [Abstract] [Full Text] [Related]

  • 8. Targeting Protein Neddylation for Cancer Therapy.
    Zhou L, Jia L.
    Adv Exp Med Biol; 2020 Feb 13; 1217():297-315. PubMed ID: 31898235
    [Abstract] [Full Text] [Related]

  • 9. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer.
    Soucy TA, Smith PG, Rolfe M.
    Clin Cancer Res; 2009 Jun 15; 15(12):3912-6. PubMed ID: 19509147
    [Abstract] [Full Text] [Related]

  • 10. Cullin-RING Ligases as attractive anti-cancer targets.
    Zhao Y, Sun Y.
    Curr Pharm Des; 2013 Jun 15; 19(18):3215-25. PubMed ID: 23151137
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression.
    Jia L, Li H, Sun Y.
    Neoplasia; 2011 Jun 15; 13(6):561-9. PubMed ID: 21677879
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Nedd8-Activating Enzyme Is a Druggable Host Dependency Factor of Human and Mouse Cytomegalovirus.
    Flores-Martínez YA, Le-Trilling VTK, Trilling M.
    Viruses; 2021 Aug 14; 13(8):. PubMed ID: 34452475
    [Abstract] [Full Text] [Related]

  • 16. UBE2M Is a Stress-Inducible Dual E2 for Neddylation and Ubiquitylation that Promotes Targeted Degradation of UBE2F.
    Zhou W, Xu J, Tan M, Li H, Li H, Wei W, Sun Y.
    Mol Cell; 2018 Jun 21; 70(6):1008-1024.e6. PubMed ID: 29932898
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. SOMCL-19-133, a novel, selective, and orally available inhibitor of NEDD8-activating enzyme (NAE) for cancer therapy.
    Zhou LN, Xiong C, Cheng YJ, Song SS, Bao XB, Huan XJ, Wang TY, Zhang A, Miao ZH, He JX.
    Neoplasia; 2022 Oct 21; 32():100823. PubMed ID: 35907292
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.